Background The current study was aimed at investigating the feasibility of hippocampus‐avoidance whole‐brain radiation therapy with a simultaneous integrated boost (HA‐WBRT+SIB) for metastases and at assessing tumor control in comparison with conventional whole‐brain radiation therapy (WBRT) in patients with multiple brain metastases. Methods Between August 2012 and December 2016, 66 patients were treated within a monocentric feasibility trial with HA‐WBRT+SIB: hippocampus‐avoidance WBRT...
Sat Mar 07, 2020 01:01
Background Adults with impaired performance status (PS) often receive immune checkpoint inhibitors (ICIs) for advanced non–small cell lung cancer (NSCLC) despite limited efficacy data and unknown effects on end‐of‐life care. Methods This was a retrospective, single‐site study of 237 patients with advanced NSCLC who initiated ICI treatment from 2015 to 2017. Cox regression was used to compare the overall survival (OS) of patients who had impaired PS (≥2) at the start of ICI treatment with...
Sat Mar 07, 2020 01:01
Abstract Background Multiple mechanisms of immunosuppression have been identified in the tumor microenvironment including regulatory B cells (Breg). Recently, we have shown that Breg suppress T cell function by production of adenosine (ADO). However, the autocrine effect of ADO on B cells and the role of Breg in head and neck cancer remains unclear. Methods ...
Sat Mar 07, 2020 02:00
Abstract Tumor-treating fields (TTFields) are alternating electric fields in a specific frequency range (100–300 kHz) delivered to the human body through transducer arrays. In this study, we evaluated whether TTFields-mediated cell death can elicit antitumoral immunity and hence would be effectively combined with anti-PD-1 therapy. We demonstrate that in TTFields-treated cancer cells, damage-associated molecular patterns including high-mobility group B1 and adenosine triphosphate...
Fri Mar 06, 2020 02:00
Cover of this issue. Colocalization of Fas (red) and cFLIPL (green) at the cell membrane in NK‐cell lymphoma‐derived cells after Fas ligation. See also Masuda et al. (pp. https://doi.org/10.1111/cas.14296807–816 of this issue).
Sun Mar 08, 2020 13:21
Cancers, Vol. 12, Pages 627: Impaired Anti-Tumor T cell Response in Hepatocellular Carcinoma Cancers doi: 10.3390/cancers12030627 Authors: Chaoul Mancarella Lupo Giannelli Dituri Different subsets of lymphocytes have the capacity to promote or counteract the progression of solid cancers, including hepatocellular carcinoma (HCC). Therefore, to determine the infiltrative ability and functional status of major immune cell subtypes into tumor may lead to novel insights...
Sun Mar 08, 2020 02:00
Cancers, Vol. 12, Pages 625: Preoperative Serum Thyroglobulin and Its Correlation with the Burden and Extent of Differentiated Thyroid Cancer Cancers doi: 10.3390/cancers12030625 Authors: Hosu Kim So Young Park Jun-Ho Choe Jee Soo Kim Soo Yeon Hahn Sun Wook Kim Jae Hoon Chung Jaehoon Jung Tae Hyuk Kim Lymph node metastasis (LNM) in differentiated thyroid cancer (DTC) is usually detected with preoperative ultrasonography; however, this has limited...
Sun Mar 08, 2020 02:00
Cancers, Vol. 12, Pages 626: The Pre-Treatment C-Reactive Protein Represents a Prognostic Factor in Patients with Oral and Oropharyngeal Cancer Treated with Radiotherapy Cancers doi: 10.3390/cancers12030626 Authors: Olivia Knittelfelder Daniela Delago Gabriele Jakse Katarzyna Lukasiak Eva-Maria Thurner Dietmar Thurnher Martin Pichler Wilfried Renner Heidi Stranzl-Lawatsch Tanja Langsenlehner The purpose of the present study was to evaluate the...
Sun Mar 08, 2020 02:00
Cancers, Vol. 12, Pages 624: Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene Cancers doi: 10.3390/cancers12030624 Authors: Alessandro Liquori Mariam Ibañez Claudia Sargas Miguel Ángel Sanz Eva Barragán José Cervera Although acute promyelocytic leukemia (APL) is one of the most characterized forms of acute myeloid leukemia (AML), the molecular mechanisms involved in the development and progression of this...
Sun Mar 08, 2020 02:00
Cancers, Vol. 12, Pages 623: Retinol-Binding Protein 4 Accelerates Metastatic Spread and Increases Impairment of Blood Flow in Mouse Mammary Gland Tumors Cancers doi: 10.3390/cancers12030623 Authors: Diana Papiernik Anna Urbaniak Dagmara Kłopotowska Anna Nasulewicz-Goldeman Marcin Ekiert Marcin Nowak Joanna Jarosz Monika Cuprych Aleksandra Strzykalska Maciej Ugorski Rafał Matkowski Joanna Wietrzyk Retinol-binding protein 4 (RBP4) is proposed...
Sat Mar 07, 2020 02:00
Cancers, Vol. 12, Pages 622: A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection Cancers doi: 10.3390/cancers12030622 Authors: Lun Zhang Jiamin Zheng Rashid Ahmed Guoyu Huang Jennifer Reid Rupasri Mandal Andrew Maksymuik Daniel S. Sitar Paramjit S. Tappia Bram Ramjiawan Philippe Joubert Alessandro Russo Christian D. Rolfo David S. Wishart The objective of this research is to use metabolomic techniques...
Sat Mar 07, 2020 02:00
Cancers, Vol. 12, Pages 621: High Prevalence of Alterations in DNA Mismatch Repair Genes of Lynch Syndrome in Pediatric Patients with Adrenocortical Tumors Carrying a Germline Mutation on TP53 Cancers doi: 10.3390/cancers12030621 Authors: Vania Balderrama Brondani Luciana Montenegro Amanda Meneses Ferreira Lacombe Breno Marchiori Magalhães Mirian Yumie Nishi Mariana Ferreira de Assis Funari Amanda de Moraes Narcizo Lais Cavalca Cardoso Sheila Aparecida Coelho...
Sat Mar 07, 2020 02:00
Cancers, Vol. 12, Pages 620: RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers Cancers doi: 10.3390/cancers12030620 Authors: Wendell D. Jones Chad M. Michener Charles Biscotti Iona Braicu Jalid Sehouli Mahrukh K. Ganapathi Ram N. Ganapathi Immune cell infiltrates within the tumor microenvironment can influence treatment response and outcome in several cancers. In this study, we developed...
Sat Mar 07, 2020 02:00
Cancers, Vol. 12, Pages 619: Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives Cancers doi: 10.3390/cancers12030619 Authors: Mary K. McKenna Amanda Rosewell-Shaw Masataka Suzuki Oncolytic adenoviruses (OAd) selectively target and lyse tumor cells and enhance anti- tumor immune responses. OAds have been used as promising cancer gene therapies for many years and there are a multitude of encouraging pre-clinical studies. However,...
Sat Mar 07, 2020 02:00
Cancers, Vol. 12, Pages 618: Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented Cancers doi: 10.3390/cancers12030618 Authors: Dominique Farge Barbara Bournet Thierry Conroy Eric Vicaut Janusz Rak George Zogoulous Jefferey Barkun Mehdi Ouaissi Louis Buscail Corinne Frere Exocrine pancreatic ductal adenocarcinoma, simply referred to as pancreatic cancer (PC) has the worst prognosis of...
Fri Mar 06, 2020 02:00
Cancers, Vol. 12, Pages 616: Radiotherapy Is Associated with an Accelerated Risk of Ischemic Stroke in Oral Cavity Cancer Survivors after Primary Surgery Cancers doi: 10.3390/cancers12030616 Authors: Feng-Che Kuan Kuan-Der Lee Shiang-Fu Huang Ping-Tsung Chen Cih-En Huang Ting-Yao Wang Min-Chi Chen The number of oral cavity carcinoma (OCC) survivors continues to increase due to advances in definitive surgery and radiation therapy (RT), however the risk of...
Fri Mar 06, 2020 02:00
Cancers, Vol. 12, Pages 617: Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer Cancers doi: 10.3390/cancers12030617 Authors: Vernieri Prisciandaro Nichetti Lobefaro Peverelli Ligorio Zattarin Cona Sepe Corti Manglaviti Brambilla Re Belfiore Pruneri Celio Mariani Bianchi ...
Fri Mar 06, 2020 02:00
Cancers, Vol. 12, Pages 614: EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy Cancers doi: 10.3390/cancers12030614 Authors: Andrea Uhlyarik Violetta Piurko Zsuzsanna Papai Erzsebet Raso Erika Lahm Edina Kiss Marta Sikter Jozsef Vachaja Istvan Kenessey Jozsef Timar The selection of colorectal cancer patients for anti-epidermal growth factor receptor (EGFR) antibody...
Fri Mar 06, 2020 02:00
Cancers, Vol. 12, Pages 615: Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition Cancers doi: 10.3390/cancers12030615 Authors: Jun Xing Vikas Bhuria Khac Cuong Bui Mai Ly Thi Nguyen Zexi Hu Chih-Jen Hsieh Kathrin Wittstein Marc Stadler Ludwig Wilkens Jun Li Markus Kalesse Przemyslaw Bozko Ruben R. Plentz Background: Hepatocellular carcinoma (HCC) represents a major health burden with limited...
Fri Mar 06, 2020 02:00
Cancers, Vol. 12, Pages 612: Preventing Venous Thromboembolism in Ambulatory Patients with Cancer: A Narrative Review Cancers doi: 10.3390/cancers12030612 Authors: Rossel Robert-Ebadi Marti Venous thromboembolism (VTE) is frequent among patients with cancer. Ambulatory cancer patients starting chemotherapy have a 5% to 10% risk of cancer associated thrombosis (CAT) within the first year after cancer diagnosis. This risk may vary according to patient characteristics, cancer...
Fri Mar 06, 2020 02:00
Cancers, Vol. 12, Pages 613: Globular Adiponectin Inhibits Breast Cancer Cell Growth through Modulation of Inflammasome Activation: Critical Role of Sestrin2 and AMPK Signaling Cancers doi: 10.3390/cancers12030613 Authors: Duc-Vinh Pham Pawan Kumar Raut Mahesh Pandit Jae-Hoon Chang Nikita Katila Dong-Young Choi Jee-Heon Jeong Pil-Hoon Park Adiponectin, an adipokine predominantly derived from adipose tissue, exhibits potent antitumor properties in breast...
Fri Mar 06, 2020 02:00
Cancers, Vol. 12, Pages 610: Human Endogenous Retroviruses (HERVs): Shaping the Innate Immune Response in Cancers Cancers doi: 10.3390/cancers12030610 Authors: Vincent Alcazer Paola Bonaventura Stephane Depil Human Endogenous Retroviruses (HERVs) are accounting for 8% of the human genome. These sequences are remnants from ancient germline infections by exogenous retroviruses. After million years of evolution and multiple integrations, HERVs have acquired many damages rendering...
Fri Mar 06, 2020 02:00
Cancers, Vol. 12, Pages 611: Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology Cancers doi: 10.3390/cancers12030611 Authors: Gabriele Calaminus Dominik T. Schneider Dietrich von Schweinitz Heribert Jürgens Nacera Infed Stefan Schönberger Thomas A. Olson Peter Albers Christian Vokuhl Raimund...
Fri Mar 06, 2020 02:00
Cancers, Vol. 12, Pages 607: Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy Cancers doi: 10.3390/cancers12030607 Authors: Chia-Hsin Lin Tsung-Min Hung Yu-Chuan Chang Chia-Hsun Hsieh Ming-Chieh Shih Shih-Ming Huang Chan-Keng Yang Ching-Fu Chang Sheng-Chieh Chan Wing-Keen Yap We aimed to investigate the prognostic value of the relative...
Fri Mar 06, 2020 02:00
Cancers, Vol. 12, Pages 608: Synthetic Lethality Screening Identifies FDA-Approved Drugs that Overcome ATP7B-Mediated Tolerance of Tumor Cells to Cisplatin Cancers doi: 10.3390/cancers12030608 Authors: Marta Mariniello Raffaella Petruzzelli Luca G. Wanderlingh Raffaele La Montagna Annamaria Carissimo Francesca Pane Angela Amoresano Ekaterina Y. Ilyechova Michael M. Galagudza Federico Catalano Roberta Crispino Ludmila V. Puchkova Diego L. Medina...
Fri Mar 06, 2020 02:00
Cancers, Vol. 12, Pages 609: Ductal Carcinoma In Situ of the Breast: An Update with Emphasis on Radiological and Morphological Features as Predictive Prognostic Factors Cancers doi: 10.3390/cancers12030609 Authors: Lucia Salvatorelli Lidia Puzzo Giada Maria Vecchio Rosario Caltabiano Valentina Virzì Gaetano Magro Ductal carcinoma in situ (DCIS) shows overlapping epidemiology with invasive ductal carcinoma of the breast, sharing similar risk factorssuch as age,...
Fri Mar 06, 2020 02:00
Cancers, Vol. 12, Pages 606: Combined wIRA-Hyperthermia and Hypofractionated Re-Irradiation in the Treatment of Locally Recurrent Breast Cancer: Evaluation of Therapeutic Outcome Based on a Novel Size Classification Cancers doi: 10.3390/cancers12030606 Authors: Markus Notter Andreas R. Thomsen Mirko Nitsche Robert M. Hermann Hendrik A. Wolff Gregor Habl Karin Münch Anca-L. Grosu Peter Vaupel Effective tumor control in patients suffering from unresectable...
Fri Mar 06, 2020 02:00
Abstract This thorough QT (TQT) study evaluated the effect of zanubrutinib on electrocardiogram (ECG) parameters by using concentration‐QTc (C‐QTc) analysis as the primary analysis for this study. Part A of the study determined the safety and tolerability of a single supratherapeutic dose of zanubrutinib (480 mg) in healthy volunteers. Part B was a randomized, blinded, placebo‐ and positive‐controlled, four‐way crossover, TQT study of single therapeutic (160‐mg) and supratherapeutic (480‐mg) doses...
Sat Mar 07, 2020 14:40
Purpose: Evaluate response of mismatch repair deficient (dMMR) rectal cancer to neoadjuvant chemotherapy. Experimental Design: dMMR rectal tumors at Memorial Sloan Kettering were retrospectively reviewed for characteristics, treatment, and outcomes. Fifty dMMR rectal cancer patients were identified by immunohistochemistry and/or microsatellite instability analysis, with initial treatment response compared to a matched pMMR rectal cancer cohort. Germline and somatic mutation analyses were evaluated....
Fri Mar 06, 2020 16:35
Purpose: The incidence of lung cancer has dramatically increased in women. Preclinical data have suggested that combining EGFR-TKI with an anti-estrogen may overcome resistance to EGFR-TKI. Experimental Design: The IFCT-1003 LADIE trial was a 2x2 arms parallel open-label randomized phase II trial. EGFR-TKI-naïve post-menopausal women with advanced lung cancer were treated with gefitinib (G) vs. G + fulvestrant (G+F) in the EGFR mutated group (EGFR+) or with erlotinib (E) vs. E + fulvestrant (E+F)...
Fri Mar 06, 2020 16:35
Purpose: In this phase I study (NCT01307267) we evaluated safety, pharmacokinetics, clinical activity, and pharmacodynamics of treatment with utomilumab plus rituximab in patients with relapsed/refractory follicular (FL) and other CD20+ non-Hodgkin lymphomas (NHLs). Experimental Design: Primary objectives were to assess treatment safety and tolerability for estimating the maximum tolerated dose (MTD), using a modified time-to-event continual reassessment method, and selecting the recommended phase...
Fri Mar 06, 2020 16:35
Publication date: Available online 5 March 2020Source: Critical Reviews in Oncology/HematologyAuthor(s): Cole Wayant, Andrew Ross, Matt Vassar
Fri Mar 06, 2020 13:54
Publication date: April 2020Source: European Journal of Cancer, Volume 129Author(s): Jordan H. Creed, Stephanie A. Smith-Warner, Travis A. Gerke, Kathleen M. Egan
Sat Mar 07, 2020 17:15
Publication date: April 2020Source: European Journal of Cancer, Volume 129Author(s): Emeline Colomba, Grégoire Marret, Giulia Baciarello, Pernelle Lavaud, Christophe Massard, Yohann Loriot, Laurence Albiges, Edith Carton, Jérome Alexandre, Olivier Huillard, Stéphane Culine, Karim Fizazi
Sat Mar 07, 2020 17:15
Publication date: Available online 6 March 2020Source: European Journal of CancerAuthor(s): Pascal Hammel, Fabienne Portales, Laurent Mineur, Jean-Philippe Metges, Thierry Andre, Christelle De La Fouchardiere, Christophe Louvet, Farid El Hajbi, Roger Faroux, Rosine Guimbaud, David Tougeron, Olivier Bouche, Thierry Lecomte, Christine Rebischung, Christophe Tournigand, Jerome Cros, Richard Kay, Adam Hamm, Anu Gupta, Jean-Baptiste Bachet
Sat Mar 07, 2020 17:15
Publication date: April 2020Source: European Journal of Cancer, Volume 129Author(s): Sylvie Negrier, Nathalie Rioux-Leclercq, Céline Ferlay, Marine Gross-Goupil, Gwenaëlle Gravis, Lionel Geoffrois, Christine Chevreau, Helen Boyle, Frederic Rolland, Ellen Blanc, Alain Ravaud, Slimane Dermeche, Aude Flechon, Laurence Albiges, David Pérol, Bernard Escudier, GETUG collaborative group
Fri Mar 06, 2020 16:31
Publication date: March 2020Source: European Journal of Cancer, Volume 128Author(s): Jun Ni, Li Zhang, Xiaotong Zhang
Fri Mar 06, 2020 16:31
Publication date: March 2020Source: European Journal of Cancer, Volume 128Author(s): Xin Liu, Yifan Cao, Ruochen Li, Yong Gu, Yifan Chen, Yangyang Qi, Kunpeng Lv, Jieti Wang, Kuan Yu, Chao Lin, Hao Liu, Heng Zhang, Hongyong He, Lingli Chen, Peipei Zhang, Zhenbin Shen, Jing Qin, Yihong Sun, He Li, Hua Huang
Fri Mar 06, 2020 16:31
Publication date: March 2020Source: European Journal of Cancer, Volume 128Author(s): Alessio Cortellini, Melissa Bersanelli, Daniele Santini, Sebastiano Buti, Marcello Tiseo, Katia Cannita, Fabiana Perrone, Raffaele Giusti, Michele De Tursi, Federica Zoratto, Riccardo Marconcini, Marco Russano, Tea Zeppola, Cecilia Anesi, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Federica De Galitiis, Maria Giuseppa Vitale
Fri Mar 06, 2020 16:31
Publication date: March 2020Source: European Journal of Cancer, Volume 128Author(s): Pernille T. Jensen, Tine H. Schnack, Ligita P. Frøding, Signe F. Bjørn, Henrik Lajer, Algirdas Markauskas, Kirsten M. Jochumsen, Katrine Fuglsang, Jacob Dinesen, Charlotte H. Søgaard, Erik Søgaard-Andersen, Marianne M. Jensen, Aage Knudsen, Laura H. Øster, Claus Høgdall
Fri Mar 06, 2020 16:31
Publication date: March 2020Source: European Journal of Cancer, Volume 128Author(s): Claudia Pasqualini, Rhoikos Furtwängler, Harm van Tinteren, Roberto A.P. Teixeira, Tomas Acha, Lisa Howell, Gordan Vujanic, Jan Godzinski, Patrick Melchior, Anne M. Smets, Aurore Coulomb-L’Hermine, Hervé Brisse, Kathy Pritchard-Jones, Christophe Bergeron, Beatriz de Camargo, Marry M. van den Heuvel-Eibrink, Norbert Graf, Arnauld C. Verschuur
Fri Mar 06, 2020 16:31
Publication date: March 2020Source: European Journal of Cancer, Volume 128Author(s): A. Gilbert, K. Drinkwater, L. McParland, R. Adams, R. Glynne-Jones, M. Harrison, M.A. Hawkins, D. Sebag-Montefiore, D.C. Gilbert, R. Muirhead
Fri Mar 06, 2020 16:31
Publication date: March 2020Source: European Journal of Cancer, Volume 128Author(s): Amy C. Lord, Nikki Knijn, Gina Brown, Iris D. Nagtegaal
Fri Mar 06, 2020 16:31
Publication date: Available online 6 March 2020Source: European Journal of Surgical OncologyAuthor(s): Mohammad Ghiasloo, Diana Pavlenko, Marzia Verhaeghe, Zoé Van Langenhove, Ortwin Uyttebroek, Giammauro Berardi, Roberto I. Troisi, Wim Ceelen
Fri Mar 06, 2020 17:31
Publication date: Available online 6 March 2020Source: European Journal of Surgical OncologyAuthor(s): S. Hoendervangers, C.L. Sparreboom, M.P.W. Intven, J.F. Lange, H.M. Verkooijen, P.G. Doornebosch, W.M.U. van Grevenstein, the Dutch ColoRectal Audit
Fri Mar 06, 2020 17:31
Publication date: Available online 6 March 2020Source: European Journal of Surgical OncologyAuthor(s): Nikki S. IJzerman, Mahmoud Mohammadi, Dimitri Tzanis, Hans Gelderblom, Marco Fiore, Elena Fumagalli, Piotr Rutkowski, Elzbieta Bylina, Ioannis Zavrakidis, Neeltje Steeghs, Han Bonenkamp, Boudewijn van Etten, Dirk J. Grünhagen, Shahnawaz Rasheed, Paris Tekkis, Charles Honoré, Winan van Houdt, Jos van der Hage, Sylvie Bonvalot, Yvonne Schrage
Fri Mar 06, 2020 17:31
Publication date: Available online 5 March 2020Source: European Journal of Surgical OncologyAuthor(s): Xiang Gao, Paolo Goffredo, Amanda R. Kahl, Mary E. Charlton, Ronald J. Weigel, Imran Hassan
Fri Mar 06, 2020 17:31
Future Oncology, Ahead of Print.
Fri Mar 06, 2020 12:45
Future Oncology, Ahead of Print.
Fri Mar 06, 2020 12:32
Future Oncology, Ahead of Print.
Fri Mar 06, 2020 05:14
Related ArticlesOCEAN: a randomized Phase III study of melphalan flufenamide + dexamethasone to treat relapsed refractory multiple myeloma. Future Oncol. 2020 Mar 06;: Authors: Schjesvold F, Robak P, Pour L, Aschan J, Sonneveld P Abstract Melphalan flufenamide (formerly melflufen) is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. It has emerged as a potential new multiple myeloma treatment, particularly for...
Sat Mar 07, 2020 15:19
Related ArticlesThe post-treatment neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after treatment of stage III non-small-cell lung cancer with conventionally fractionated radiotherapy. Future Oncol. 2020 Mar 06;: Authors: Wang D, Guo D, Li A, Wang P, Teng F, Yu J Abstract Aim: To investigate the predictive potential of post-treatment neutrophil-to-lymphocyte ratio (NLR) and changes in this ratio (ΔNLR) for stage III non-small-cell...
Sat Mar 07, 2020 15:19
Related ArticlesA nomogram for predicting overall survival in patients with uterine leiomyosarcoma: a SEER population-based study. Future Oncol. 2020 Mar 06;: Authors: Lu YJ, Wang H, Fang LY, Wang WJ, Song W, Wang Y, Huang YQ, Din ZL Abstract Aim: To establish and validate a nomogram for the estimation of overall survival of patients with uterine leiomyosarcoma (uLMS). Methods: Information on patients diagnosed as uLMS was retrospectively retrieved from...
Sat Mar 07, 2020 15:19
Modulation of prostate stromal cells (PrSCs) within tumor tissues is gaining attention for the treatment of solid tumors. Using our original in vitro co‐culture system, we previously reported that leucinostatin (LCS)‐A, a peptide mycotoxin, inhibited prostate cancer DU‐145 cell growth through reduction of insulin‐like growth factor 1 (IGF‐1) expression in PrSCs. To further obtain additional bioactive compounds from LCS‐A, we designed and synthesized a series of LCS‐A derivatives as compounds that...
Sat Mar 07, 2020 10:24
Results from two recently established population‐based registries in Mozambique are reported: Beira in the central region (2014‐2017) and Maputo, the capital city, in the South (2015‐2017). The results are compared with those from Maputo (Lourenço Marques at the time) in 1956‐1960 (appearing Cancer Incidence in Five Continents Vol 1), and with estimated incidence rates from other regions of Africa. The elevated prevalence of HIV infection (12.6% of adults in 2018) results in high rates for HIV‐related...
Sat Mar 07, 2020 01:20
Chronic inflammation plays an important role in primary liver cancer (PLC) etiology, and can be influenced by dietary habits. No prospective study has investigated the association of dietary inflammatory index (DII) with PLC incidence and mortality. Therefore, we used prospective data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial to fill this gap. The DII was calculated from a validated 137‐item food frequency questionnaire in a cohort of 103902 individuals. Cox regression...
Sat Mar 07, 2020 01:20
The current study aimed to investigate the role of cooking with mustard oil and other dietary factors in relation to gallbladder cancer (GBC) in high‐ and low‐incidence regions of India. A case‐control study was conducted including 1,170 histologically confirmed cases and 2,525 group‐matched visitor controls from the largest cancer hospital in India. Dietary data were collected through a food frequency questionnaire. For oil consumption we enquired about monthly consumption of 11 different types...
Sat Mar 07, 2020 01:20
Similar family‐based cancer and genealogy data from Norway and Utah allowed comparisons of the incidence of testicular cancer (TC), and exploration of the role of Scandinavian ancestry and family history of TC in TC risk. This study utilizes data from the Utah Population Database and Norwegian Population Registers. All males born during 1951‐2015 were followed for TC until the age of 29 years. A total of 1,974,287 and 832,836 males were born in Norway and Utah, respectively, of whom 2,686 individuals...
Sat Mar 07, 2020 01:20
Many countries are transitioning to HPV testing for cervical cancer screening, despite a lack of long‐term experience. To anticipate multi‐round screening performance, we analyzed 15‐year HPV testing results at Kaiser Permanente Northern California (KPNC). We evaluated HPV test result patterns among women aged 30‐64 undergoing triennial HPV/cytology cotesting at KPNC during 2003‐2018. We calculated incidence rates and proportion of CIN3+ diagnoses associated with the most frequent HPV testing patterns...
Sat Mar 07, 2020 01:20
Epacadostat is a potent and highly selective inhibitor of indoleamine 2,3‐dioxygenase 1 (IDO1). Here we report results from the open‐label, dose‐escalation, phase 1b ECHO‐110 study evaluating epacadostat plus atezolizumab in patients with previously treated stage IIIB/IV non‐small cell lung cancer (NSCLC). Eligible patients had received ≥1 prior line of platinum‐based chemotherapy (≥2 cycles) and no prior checkpoint/IDO inhibitors treatment. Oral epacadostat (25, 50, 75, 100, 200, or 300 mg) was...
Sat Mar 07, 2020 01:20
Abstract Sunscreen use is an important aspect of sun protective behavior. Previous studies revealed deficits in sunscreen use. Our aim was to quantify sunscreen use in a nationwide representative study in Germany as well as to develop and test an item battery on reasons for none use of sunscreen. We analyzed data of the National Cancer Aid Monitoring (NCAM; wave 4; n = 3000, aged 14–45). To describe those who only use sunscreen rarely or never, we used chi2 statistics and logistic...
Fri Mar 06, 2020 02:00
Abstract Introduction Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive cancer. There are various sub-cellular events (both genetic and epigenetic) that get dysregulated leading to tumorigenesis. Methylation in promoters of tumor suppressor genes is one of these epigenetic phenomena contributing to the pathogenesis of cancer. Genes analyzed for promoter methylation status in this study namely SPARC (Secreted Protein Acidic...
Sat Mar 07, 2020 02:00
Abstract Purpose MicroRNAs (miRNAs) participate in a variety of biological processes, including tumorigenesis, progression, invasion, and drug resistance to multiple cancers. Phosphatase and tensin homolog (PTEN) is a cancer suppressor gene that has been certified to be regulated by miRNAs in various tumors, including colorectal cancer (CRC). In this review, we screened articles focusing on low PTEN expression in CRC, observed the expression...
Sat Mar 07, 2020 02:00
Abstract Aims Local therapy including surgery or radiotherapy has been reported for the treatment of non-small cell lung cancer (NSCLC) with synchronous solitary metastasis, while studies with other local ablative treatment are rare. Here, we summarized our single-center experience of microwave ablation (MWA) for both primary and metastatic lesions in NSCLC patients with synchronous solitary extracranial metastases. ...
Sat Mar 07, 2020 02:00
Abstract Background/objective Elderly patients with cancer are often at risk for undertreatment because of frailty, an aging-specific problem. However, current real-world conditions of recurrent ovarian cancer treatment in elderly patients remain unclear. This study aimed to clarify treatment patterns in elderly patients with recurrent ovarian cancer. Patients and methods...
Fri Mar 06, 2020 02:00
Abstract Purpose Adenoid cystic carcinoma (AdCC) is generally slow growing but has highly metastatic potential to distant organs. Several factors and biomarkers are associated with metastasis and treatment outcomes, although further definition is needed. Therefore, this study aimed to evaluate the risk factors for survival and distant metastasis in patients with head and neck AdCC. ...
Fri Mar 06, 2020 02:00
Abstract Purpose Aberrant DNA methylation could regulate the expression of tumor suppressor gene DLEC1 and oncogene PBX3 and was related to the occurrence and prognosis of gastric cancer (GC). In this study, the associations between DLEC1 and PBX3 promoter methylation in peripheral blood leukocytes (PBLs) and the risk and prognosis of GC were investigated. Methods ...
Fri Mar 06, 2020 02:00
Abstract Purpose Uncertainty exists regarding comparative effectiveness of cetuximab versus bevacizumab in metastatic colorectal cancer (mCRC). We conducted a retrospective head-to-head multi-cohort study comparing clinical outcomes from both antibodies Methods Cohorts were defined by treatment line and subgroups by (K)RAS status and tumour sidedness....
Fri Mar 06, 2020 02:00
Molecular profiling of DNA and RNA has provided valuable new insights into the genetic basis of non-malignant and malignant disorders, as well as an increased understanding of basic mechanisms that regulate hu...
Thu Mar 05, 2020 02:00
Abstract Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is an extremely rare subtype of non-small-cell lung cancer (NSCLC) but differs from other NSCLC types. Most patients with PPLELC have almost no obvious clinical manifestations, and are often diagnosed in the advanced stage. Complete resection is the standard treatment for cases with early stage disease, while chemotherapy and radiotherapy are effective to some extent in late stage disease. High expression of...
Sat Mar 07, 2020 02:00
Abstract To perform a comprehensive genomic analysis of colorectal cancer (CRC) tumor to detect genetic variants and identify novel resistant mutations associated with cetuximab‐resistance in CRC patients. A retrospective study was performed using whole exome sequencing (WES) to identify common genetic factors from 22 cetuximab‐sensitive and 10 cetuximab‐resistant patients. In all 10 cetuximab‐resistant patients, we discovered there are 37 significantly mutated genes (SMGs). CYP4A11 was the most...
Fri Mar 06, 2020 11:05
Publication date: Available online 7 March 2020Source: Practical Radiation OncologyAuthor(s): Avani Dholakia Rao, Eun Ji Shin, Jeffrey Meyer, Elizabeth L. Thompson, Wei Fu, Chen Hu, Elliot K. Fishman, Matthew Weiss, Christopher Wolfgang, Richard Burkhart, Jin He, Tossapol Kerdsirichairat, Joseph M. Herman, Kai Ding, Amol Narang
Sat Mar 07, 2020 12:22
Publication date: Available online 6 March 2020Source: Practical Radiation OncologyAuthor(s): Bidhu K. Mohanti
Sat Mar 07, 2020 12:22
A major cause of death related to cancer is the distant recurrence of the primary cancer [1]. Metastatic cancer is typically related to a poor prognosis in part due to the unpredictable nature of the disease [2]. This often leads to an inability to explicitly define the ideal treatment. Our recent study suggested that microscopic disease extensions (MDEs) of a primary non-small cell lung cancer (NSCLC) tumor could be related to distant metastasis [3], although there has been little research done...
Fri Feb 07, 2020 02:00
In 1997, EURATOM issued a directive (97/43) requiring member states to organize clinical audits in radiotherapy. The European Medical Exposure Directive of 2013 (Council Directive 2013/59/Euratom), further defined clinical audits as “a systematic examination or review of medical radiological procedures which seeks to improve the quality and outcome of patient care through structured review, whereby medical radiological practices, procedures and results are examined against agreed standards for good...
Fri Feb 07, 2020 02:00
For over two decades now, carbon-ion radiotherapy (C-ion RT) has been used for the treatment of early-stage non-small cell lung cancer (NSCLC) [1]. Compared with stereotactic body radiotherapy, which has exhibited promising outcomes for inoperable early-stage NSCLC [2], C-ion RT facilitates delivering a higher dose to the target with extremely low lung toxicity because of its fine dose concentration [3,4]. These advantages make C-ion RT a good treatment option for patients with NSCLC. However, C-ion...
Fri Feb 07, 2020 02:00
Patients with squamous cell carcinoma of the head and neck (SCCHN) commonly present with locoregionally advanced disease. Concurrent chemoradiotherapy (CRT) has emerged as the standard of care, as reflected by improvement of overall survival (OS) rates for the concurrent use of cisplatin and radiotherapy [1]. Overall survival, however, remains low, especially for human papilloma virus (HPV) unassociated disease [1]. Attempts to improve outcomes through administering induction chemotherapy prior to...
Fri Feb 07, 2020 02:00
Fragments of mature tRNAs have long been considered as mere degradation products without physiological function. However, recent reports show that tRNA-derived small RNAs (tsRNAs) play prominent roles in diverse cellular processes across a wide spectrum of species. Contrasting the situation in other small RNA pathways the mechanisms behind these effects appear more diverse, more complex and are generally less well understood. In addition, surprisingly little is known about the expression profiles...
Fri Mar 06, 2020 23:09
DNA replication occurs on mammalian chromosomes in a cell-type distinctive temporal order known as the replication timing program. We previously found that disruption of the noncanonical lncRNA genes ASAR6 and ASAR15 results in delayed replication timing and delayed mitotic chromosome condensation of human chromosome 6 and 15, respectively. ASAR6 and ASAR15 display random monoallelic expression, and display asynchronous replication between alleles that is coordinated with other random monoallelic...
Fri Mar 06, 2020 20:38
Macrolides are one of the most successful and widely used classes of antibacterials, which kill or stop the growth of pathogenic bacteria by binding near the active site of the ribosome and interfering with protein synthesis. Dirithromycin is a derivative of the prototype macrolide erythromycin with additional hydrophobic side chain. In our recent study, we have discovered that the side chain of dirithromycin forms lone pair- stacking interaction with the aromatic imidazole ring of the His69 residue...
Fri Mar 06, 2020 18:09
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s): David L. Bushnell, Kellie L. Bodeker
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s): Chandrikha Chandrasekharan
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s): Kristen E. Limbach, Rodney F. Pommier
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s): Jennifer Hrabe
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s): Amanda M. Laird, Steven K. Libutti
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s): Tanaz Vaghaiwalla, Xavier M. Keutgen
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s): Aaron T. Scott, James R. Howe
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s): Janet Pollard, Parren McNeely, Yusuf Menda
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s): Andrew M. Bellizzi
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s): Joseph S. Dillon
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s): Thomas M. O’Dorisio, Alan G. Harris, M Sue O’Dorisio
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s): James R. Howe
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s): Timothy M. Pawlik
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s):
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s):
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s):
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s):
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s):
Sat Mar 07, 2020 16:18
Publication date: April 2020Source: Surgical Oncology Clinics of North America, Volume 29, Issue 2Author(s): James R. Howe
Sat Mar 07, 2020 16:18
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου